Autoimmune hemolytic anemia (AHA) is a common complication in chronic lymphocytic leukemia (CLL). The UK LRF CLL4 trial is the largest prospective trial in CLL to examine the prognostic impact of both a positive direct antiglobulin test (DAT) and AHA. 777 patients were randomized to receive chlorambucil or fludarabine, alone or with cyclophosphamide (FC). The incidence pre-treatment of a positive DAT was 14%. 
Introduction
Autoimmune hemolytic anemia (AHA) is a common complication in chronic lymphocytic leukemia (CLL), occurring in 10-25% of patients during the course of their disease. 1, 2 The direct antiglobulin test (DAT) may be positive at some time during the disease course in up to 35% of cases, but overt AHA occurs less frequently. Although AHA may occur in asymptomatic untreated CLL it is more common in patients with advanced stage disease, 10.5% in Binet stage B and C, compared to only 2.9% in stable stage A patients 1 . A review of our data from MRC CLL Trials over the past 20 years shows an incidence of AHA of 8.6% in 1273 patients, rising to 11% after treatment, predominantly with alkylating agents.
In 1966 a landmark paper first suggested that treatment with X-rays or alkylating agents might trigger the onset of AHA in CLL. 3 Following the advent of purine analog therapy in the 1980s there have been a number of single case reports and small series, involving over 100 patients, suggesting that AHA may occur more commonly following treatment with these agents. [4] [5] [6] [7] [8] [9] The main results of the LRF CLL4 trial conducted in the UK between 1999 and 2004 have been reported 10 , including the incidence of AHA. The trial provided an opportunity to study prospectively the incidence of a positive DAT and its relationship to the risk of developing AHA in 777 previously untreated CLL patients who received therapy with either chlorambucil or fludarabine given with or without cyclophosphamide. We present the findings from this study. Information regarding the result of the DAT test was requested at trial entry and at the time of maximum response to first treatment. Patients with a positive DAT, but without overt hemolysis, could be randomized in the trial with the recommendation that close monitoring for onset of hemolysis should be followed.
Methods

This study was approved by the Institutional Review Board of the Royal Marsden Hospital & Institute of Cancer Research and the Multi-Centre Research Ethics Committee (MREC). The trial followed UK Medical Research Council Guidelines for
AHA was defined by standard criteria: a drop in hemoglobin, associated with a positive DAT and/or increased reticulocyte count and rise in indirect bilirubin with no other cause for anemia identified. In some cases the diagnosis of AHA was supported by increased levels of lactate dehydrogenase (LDH) and low haptoglobin. Patients with AHA were eligible for the trial but received therapy for the hemolysis before initiating the allocated treatment. Cases of AHA occurring during first line treatment were identified on the form completed at the end of first line treatment. Pre-treatment AHA was not reported.
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From Treatment of patients with AHA followed conventional guidelines for idiopathic AHA; namely prednisolone at 1mg/kg body weight per day for 2-4 weeks tapered off over several weeks. Other therapies used included intravenous immunoglobulin, splenectomy, cyclosporine A and rituximab. Details of treatment for AHA were not available.
Concomitant treatments for patients entered into the trial included: allopurinol for the first 2-3 courses, cotrimoxazole throughout treatment and for 6 months after completion, and aciclovir in selected patients.
Other variables recorded at trial entry (either in all or in the majority of patients) and included in analyses were: stage of disease, age, sex, ß2 microglobulin, LDH and absolute lymphocyte count (ALC). A range of other prognostic markers were also analysed for the majority of trial patients 11 : immunoglobulin heavy chain variable gene mutation status, cytogenetics by florescence in situ hybridization (FISH), CD38 and ZAP-70 expression. A full analysis of these will follow in a separate report and is not included here.
Statistical methods
Overall survival was calculated from randomisation to death from any cause and progression free survival (PFS) was time from randomisation to relapse needing further therapy, progression or death from any cause. For non-responders and those with progressive disease (NR/PD), the date of progression was when NR/PD was recorded.
Comparisons between categorical variables were made using the Chi squared test, and between quantitative variables using the Wilcoxon rank sum test. Logistic regression models were used to determine those factors that were independently associated with a positive DAT result and with the development of AHA. Survival functions have been estimated using the Kaplan-Meier method and groups compared with the log-rank test.
Multivariate Cox regression analysis was used to determine whether prognostic factors were independently associated with outcome. A partial adjustment was made for missing values of ß2 microglobulin, the variable with the largest proportion of missing data, using the median value. All p-values are 2-sided. Two patients were lost to follow-up. Thirty percent of patients were over 70 years of age.
DAT results
The DAT result in 637 patients (82%) was recorded at trial entry. 13%, 17% and 10% respectively after treatment). Of the 299 patients tested at both time points, those treated with single-agent fludarabine were the most likely to remain DAT positive (82% versus 52% chlorambucil, 42% FC) and the most likely to change from negative to positive (9% versus 3%, 4%) ( Table 1) . Thus fludarabine increased the net incidence of positivity in these patients by 4 cases (+5%), compared to 6 fewer cases after chlorambucil (-4%) and 4 fewer after FC (-5%), but these differences were not statistically significant (p>0.05). The positive predictive value of the test (chance that a DAT positive patient will develop AHA) was 28% (38%, 29% and 12% for chlorambucil, fludarabine and FC respectively).
Incidence of AHA
The negative predictive value of the test (chance that a DAT negative patient will be AHA-free) was 93% (92%, 90% and 96% respectively). Thus the DAT test at entry correctly predicted the development of AHA or not after therapy in 83% of cases (84%, 82% and 83% respectively). Information was not recorded regarding either the time elapsed from start of treatment until onset of AHA, or the incidence of AHA after second-line treatment.
Outcomes of AHA
Patients who developed AHA were less likely than others to have responded to treatment (43/65 (66% overall response rate) versus 530/654 (81%), p=0.004) and less likely to have had a good (complete or nodular partial) response (12/65 (18%) versus 268/654 (41%), p=0.0004). Twelve AHA patients were not assessable for response (4 died less than 6 months after entry). Those patients who developed AHA did receive less therapy:
41% only had 1-3 courses of chlorambucil compared to 14% without AHA, only 38% completed 4-6 cycles of fludarabine compared to 73% of those without AHA and 56% completed 4-6 cycles of FC compared to 74% non-AHA patients.
Four deaths were attributed to AHA during first-line treatment, all on fludarabine monotherapy. These account for 1.5% of the total deaths in the trial to July 2006, or 2% of deaths in which CLL was a cause. In patients treated with single-agent fludarabine these accounted for 6% of total deaths and 7% of CLL deaths. Survival times from randomisation for these four patients were 1, 3, 3 and 5 months. Three were DAT positive, and one negative, at entry; 3 received oral and one iv fludarabine, for between one and 3 courses. Of the 4 patients, 3 presented with Stage C disease and 1 with stage B, 1 patient had unmutated V H genes, 2 mutated and 1 not known and 1 patient had a p53 deletion in 85% of cells by FISH. A DAT-positive test result at entry was associated with more advanced stage of disease, higher ß2 microglobulin and higher ALC ( Table 2 ). Multivariate analysis showed that stage of disease and ß2 microglobulin were the only clear independent predictors of DAT result, with stage C patients more likely to be DAT positive than stage A progressive or B patients (HR for stage C= 2.23, 95% CI: 1.3-3.82, p=0.004; HR for unit increase in ß2 microglobulin =1.11, 95% CI: 1.01-1.23, p=0.03). A further analysis including genetic markers showed that immunoglobulin heavy chain mutation and FISH results (deletion at 11q23) were only of borderline significance (p=0.05). However these results require careful interpretation because laboratory data are not available for all patients. A detailed analysis will be presented elsewhere. Table 3 shows that the development of AHA is associated with stage C disease, positive DAT result, higher ß2 microglobulin, treatment with chlorambucil or fludarabine monotherapy and older age. Multivariate analysis (Table 4) highlighted DAT test result, age, stage of disease and treatment as independent predictors of AHA. Genetic markers were not significant in multivariate analysis. In the 621 patients for whom the DAT result at trial entry and AHA were recorded, those treated with chlorambucil or fludarabine monotherapy were roughly three times more likely to develop AHA compared to FC For personal use only. on August 31, 2017. by guest www.bloodjournal.org From patients. Those with a negative DAT result at trial entry had a 77% reduced odds of developing AHA. The odds of developing AHA increased with age and were greater for patients with stage C disease than for earlier stage patients.
Discussion
The UK LRF CLL4 trial is the largest prospective trial in CLL to examine the incidence and prognostic impact of a positive DAT and AHA in patients requiring therapy. We report an incidence of a positive DAT of 14% and AHA of 10%, levels which are consistent with previous studies in patients with active CLL. 1, 12, 13 The number of patients with a positive DAT at trial entry was well balanced across all three treatment arms. Less than half of the patients were tested after completion of treatment, but of those tested at both time points 5% became DAT positive after therapy This observation has also been reported by Borthakur et al. 14 The DAT result had an important independent association with the development of AHA.
The approximate risk of a patient with a positive DAT developing AHA was 1 in 3. DAT negativity was a strong predictor (>90%) for not developing AHA after therapy. Only There were four deaths from autoimmune hemolysis after first-line therapy, accounting for 2% of all deaths in the trial. All these cases occurred in patients receiving fludarabine monotherapy. This study therefore agrees with the observation that AHA occurring in association with fludarabine treatment may be more severe 4, 5 . In contrast, both the incidence and the severity of AHA were lower for those patients receiving FC. There are a number of possible explanations for this. Patients achieving good remissions may be at less risk of developing AHA and therefore the most effective treatment is likely to be associated with reduction in the incidence of AHA. The treatment responses in LRF CLL4, which have been reported elsewhere 10 , showed that, although there was no significant difference in survival, the overall and complete response (CR) rates and the PFS were significantly better with FC than with either fludarabine alone or chlorambucil.
The CR rate was 38% for FC, 15% for fludarabine and 7% for chlorambucil. The German CLL and US Intergroup study groups have also reported superior response rates and PFS for FC compared to F alone. 19, 20 In the German study there was a reduction in incidence The development of AHA was associated not only with a positive DAT and treatment modality, but also with more advanced disease stage and older age. Mauro et al 12 and
Barcellini et al 13 have also reported age above 65 years as a predictor of AHA although this was not confirmed by Borthakur et al 14 .
The relationship between AHA and advanced stage has been a consistent finding across all studies. In our study, development of autoimmune hemolysis was associated with a poorer response to treatment and with both shorter PFS (9% versus 18%) and overall survival (37% versus 58%) at 5 years. In multivariate analysis AHA retained independent prognostic value for OS but not for PFS.
Three other studies have failed to show any independent effect of AHA on survival probability 12, 13, 17 Perhaps the most interesting, and somewhat surprising, observation in this study was the prognostic significance of a positive DAT, with or without associated AHA. Although overall response to treatment was the same regardless of DAT status, this did influence quality of remissions, with good (complete or nodular partial) response rates of 27% for DAT positive patients versus 39% for DAT negative patients (p=0.03). PFS and overall survival were better for DAT negative patients, even after exclusion of those who developed AHA. Multivariate analysis showed this to be a significant independent prognostic variable. This is the first report of the prognostic significance of the DAT test in CLL. The reason why a positive DAT should be a risk factor in CLL is not clear. It may be a surrogate marker for other poor prognostic features such as immunoglobulin heavy chain gene mutation status and further studies will be needed to elucidate this.
In conclusion, the FC combination has a beneficial effect on both the DAT expression and on the development of AHA during treatment of CLL. In addition, the DAT status at the time of initiation of therapy provides a new prognostic indicator for both PFS and OS.
The DAT test remains, therefore, an important pre-treatment assessment for all patients.
Patients who are DAT positive may benefit from FC or FC plus rituximab rather than fludarabine or chlorambucil monotherapy.
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